Detection of Multidrug Resistance Using Molecular Nuclear Technique.
- Author:
Jaetae LEE
1
;
Byeong Cheol AHN
Author Information
1. Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. jaetae@knu.ac.kr
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Multidrug resistance;
MDR Modulator;
Molecular imaging;
SPECT;
PET;
Bioluminescence
- MeSH:
Animals;
Colchicine;
Cyclosporine;
Daunorubicin;
Drug Resistance, Multiple*;
Drug Therapy;
Humans;
Leukotrienes;
Molecular Imaging;
P-Glycoprotein;
Positron-Emission Tomography;
Quinidine;
Tamoxifen;
Tomography, Emission-Computed, Single-Photon;
Verapamil
- From:Korean Journal of Nuclear Medicine
2004;38(2):180-189
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Although the outcome of cancer patients after cytotoxic chemotherapy is related diverse mechanisms, multidrug resistance (MDR) for chemotherapeutic drugs due to cellular P-glycoprotein (Pgp) or multidrug-resistance associated protein (MRP) is most important factor in the chemotherapy failure to cancer. A large number of pharmacologic compounds, including verapamil, quinidine, tamoxifen, cyclosporin A and quinolone derivatives have been reported to overcome MDR. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) are available for the detection of Pgp and MRP-mediated transporter. 99mTc-MIBI and other 99mTc-radiopharmaceuticals are substrates for Pgp and MRP, and have been used in clinical studies for tumor imaging, and to visualize blockade of Pgp-mediated transport after modulation of Pgp pump. Colchicine, verapamil and daunorubicin labeled with 11C have been evaluated for the quantification of Pgp-mediated transport with PET in vivo and reported to be feasible substrates with which to image Pgp function in tumors. Leukotrienes are specific substrates for MRP and N-[11C]acetyl-leukotriene E4 provides an opportunity to study MRP function non-invasively in vivo. SPECT and PET pharmaceuticals have successfully used to evaluate pharmacologic effects of MDR modulators. Imaging of MDR and reversal of MDR with bioluminescence in a living animal is also evaluated for future clinical trial. We have described recent advances in molecular imaging of MDR and reviewed recent publications regarding feasibility of SPECT and PET imaging to study the functionality of MDR transporters in vivo.
